Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report

References

• Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385(9976):1460–1471. Cited in: PMID: 25481618. doi:10.1016/S0140-6736(14)60720-0.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, Okumura F, Nishikawa T, Kobayashi K, Ichiya T, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1504–1507. Cited in: PMID: 19398440. doi:10.1136/gut.2008.172908.
   PubMed Web of Science ®Google Scholar
• Peng Y, Li JQ, Zhang PP, Zhang X, Peng LY, Chen H, Zhou JX, Zhang SZ, Yang HX, Liu JJ, et al. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: a long-term cohort study. J Intern Med. 2019;286(5):542–552. doi:10.1111/joim.12942. Cited in: PMID: 31121062.
   PubMed Web of Science ®Google Scholar
• Culver EL, Sadler R, Simpson D, Cargill T, Makuch M, Bateman AC, Ellis AJ, Collier J, Chapman RW, Klenerman P, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol. 2016;111(5):733–743. doi:10.1038/ajg.2016.40. Cited in: PMID: 27091321.
   PubMed Web of Science ®Google Scholar
• Yunyun F, Yu P, Panpan Z, Xia Z, Linyi P, Jiaxin Z, Li Z, Shangzhu Z, Jinjing L, Di W, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford)). 2019;58(1):52–60. doi:10.1093/rheumatology/key227. Cited in: PMID: 30124952.
   PubMed Web of Science ®Google Scholar
• Maruyama M, Watanabe T, Kanai K, Oguchi T, Asano J, Ito T, Ozaki Y, Muraki T, Hamano H, Arakura N, et al. Autoimmune pancreatitis can develop into chronic pancreatitis. Orphanet J Rare Dis. 2014;9:77. doi:10.1186/1750-1172-9-77. Cited in: PMID: 24884922.
   PubMed Web of Science ®Google Scholar
• Chari ST, Murray JA. Autoimmune pancreatitis, part II: the relapse. Gastroenterology. 2008;134(2):625–628. doi:10.1053/j.gastro.2007.12.014. Cited in: PMID: 18242227.
   PubMed Web of Science ®Google Scholar
• Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czakó L, Frulloni L, Go VL, Gress TM, Kim MH, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–1776. Cited in: PMID: 23232048. doi:10.1136/gutjnl-2012-303617.
   PubMed Web of Science ®Google Scholar
• Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, Deheragoda MG, Novelli M, Winstanley A, Rodriguez–Justo M, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7(10):1089–1096. doi:10.1016/j.cgh.2009.03.021. Cited in: PMID: 19345283.
   PubMed Web of Science ®Google Scholar
• Sah RP, Chari ST, Pannala R, Sugumar A, Clain JE, Levy MJ, Pearson RK, Smyrk TC, Petersen BT, Topazian MD, et al. Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis. Gastroenterology. 2010;139(1):140–148. Cited in: PMID: 20353791. doi:10.1053/j.gastro.2010.03.054.
   PubMed Web of Science ®Google Scholar
• Ryu JK, Chung JB, Park SW, Lee JK, Lee KT, Lee WJ, Moon JH, Cho KB, Kang DW, Hwang JH, et al. Review of 67 patients with autoimmune pancreatitis in Korea: a multicenter nationwide study. Pancreas. 2008;37(4):377–385. doi:10.1097/MPA.0b013e31817a0914. Cited in: PMID: 18953249.
   PubMed Web of Science ®Google Scholar
• Zen Y, Nakanuma Y. IgG4-related disease: a cross-sectional study of 114 cases. Am J Surg Pathol. 2010;34(12):1812–1819. doi:10.1097/PAS.0b013e3181f7266b. Cited in: PMID: 21107087.
   PubMed Web of Science ®Google Scholar
• Della Torre E, Mattoo H, Mahajan VS, Carruthers M, Pillai S, Stone JH. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy. 2014;69(2):269–272. doi:10.1111/all.12320. Cited in: PMID: 24266692.
   PubMed Web of Science ®Google Scholar
• Akiyama M, Yasuoka H, Yoshimoto K, Takeuchi T. Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease. Cytokine. 2018;110:416–419. Epub 2018/06/05. doi:10.1016/j.cyto.2018.05.009. Cited in: PMID: 29861381.
   PubMed Web of Science ®Google Scholar
• Chiaramonte MG, Cheever AW, Malley JD, Donaldson DD, Wynn TA. Studies of murine schistosomiasis reveal interleukin-13 blockade as a treatment for established and progressive liver fibrosis. Hepatology. 2001;34(2):273–282. Epub 2001/08/02. doi:10.1053/jhep.2001.26376. Cited in: PMID: 11481612.
   PubMed Web of Science ®Google Scholar
• Zen Y, Fujii T, Harada K, Kawano M, Yamada K, Takahira M, Nakanuma Y. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology. 2007;45(6):1538–1546. Epub 2007/05/24. doi:10.1002/hep.21697. Cited in: PMID: 17518371.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Ohno K, Takata K, Gion Y, Tachibana T, Orita Y, Yoshino T, Sato Y. Interleukin 13-positive mast cells are increased in immunoglobulin G4-related sialadenitis. Sci Rep. 2015;5:7696 doi:10.1038/srep07696. Cited in: PMID: 25571893.
   PubMed Web of Science ®Google Scholar
• Masuoka M, Shiraishi H, Ohta S, Suzuki S, Arima K, Aoki S, Toda S, Inagaki N, Kurihara Y, Hayashida S, et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest. 2012;122(7):2590–2600. doi:10.1172/jci58978. Cited in: PMID: 22684102.
   PubMed Web of Science ®Google Scholar
• Simpson RS, Lau SKC, Lee JK. Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis. 2020;79(4):549–550. Epub 2019/12/21. doi:10.1136/annrheumdis-2019-216368. Cited in: PMID: 31857343.
   PubMed Web of Science ®Google Scholar
• Simpson RS, Lee JK. Response to: ‘Dupilumab as a potential steroid-sparing treatment for IgG4-related disease’ by Della-Torre. Ann Rheum Dis. 2020:annrheumdis-202. Cited in: PMID: 32033938. doi:10.1136/annrheumdis-2020-216955.
   Web of Science ®Google Scholar
• Ebbo M, De Sainte-Marie B, Muller R, Piperoglou C, Grados A, Vely F, Schleinitz N. Comment on article: ‘Dupilumab as a novel steroid-sparing treatment for IgG4-related disease’ by Simpson et al. Ann Rheum Dis. 2020:annrheumdis-202. Cited in: PMID: 31996366. doi:10.1136/annrheumdis-2020-217010.
   Web of Science ®Google Scholar
• Della-Torre E, Lanzillotta M, Yacoub MR. Dupilumab as a potential steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis. 2020:annrheumdis-202. E Cited in: PMID: 31937521. doi:10.1136/annrheumdis-2020-216945.
   Web of Science ®Google Scholar
• Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, Matsui S, Yoshino T, Nakamura S, Kawa S, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22(1):21–30. doi:10.1007/s10165-011-0571-z. Cited in: PMID: 22218969
   PubMed Web of Science ®Google Scholar
• Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS, Kulikova M, Drijvers JM, Daccache J, Carruthers MN, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol. 2016;138(3):825–838. doi:10.1016/j.jaci.2015.12.1330. Cited in: PMID: 26971690.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lin W, Yang H, Wang M, Zhang P, Feng R, Chen H, Peng L, Zhang X, Zhao Y, et al. Aberrant expansion and function of follicular helper T cell subsets in IgG4-related disease. Arthritis Rheumatol. 2018;70(11):1853–1865. doi:10.1002/art.40556. Cited in: PMID: 29781221.
   PubMed Web of Science ®Google Scholar
• Grados A, Ebbo M, Piperoglou C, Groh M, Regent A, Samson M, Terrier B, Loundou A, Morel N, Audia S, et al. T cell polarization toward TH2/TFH2 and TH17/TFH17 in patients with IgG4-related disease. Front Immunol. 2017;8:235 doi:10.3389/fimmu.2017.00235. Cited in: PMID: 28348556.
   PubMed Web of Science ®Google Scholar
• Furukawa S, Moriyama M, Tanaka A, Maehara T, Tsuboi H, Iizuka M, Hayashida JN, Ohta M, Saeki T, Notohara K, et al. Preferential M2 macrophages contribute to fibrosis in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Clin Immunol. 2015;156(1):9–18. doi:10.1016/j.clim.2014.10.008. Cited in: PMID: 25450336.
   PubMed Web of Science ®Google Scholar
• Michailidou D, Schwartz DM, Mustelin T, Hughes GC. Allergic aspects of IgG4-related disease: implications for pathogenesis and therapy. Front Immunol. 2021;12(2399):693192. doi: 10.3389/fimmu.2021.693192. Cited in: PMID: 34305927.
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Rigamonti E, Perugino C, Baghai-Sain S, Sun N, Kaneko N, Maehara T, Rovati L, Ponzoni M, Milani R, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol. 2020;145(3):968–981. doi:10.1016/j.jaci.2019.07.004. Cited in: PMID: 31319101.
   PubMed Web of Science ®Google Scholar